Product identity and label fit
Zepbound is tirzepatide; Saxenda is liraglutide
Zepbound and Saxenda are both branded prescription pathways used in weight-management care when label criteria fit, but they are different products. Zepbound is branded tirzepatide and acts on GIP and GLP-1 receptors. Saxenda is branded liraglutide and acts as a GLP-1 receptor agonist. That distinction matters because age criteria, labeled uses, side-effect counseling, product instructions, pharmacy availability, coverage, and follow-up expectations can differ. Patients should not treat the names as interchangeable or switch between them without a clinician-led plan.
- Zepbound discussions usually focus on adult chronic weight-management criteria, obstructive-sleep-apnea context when relevant, prior tirzepatide or GLP-1 response, gastrointestinal tolerance, pregnancy or contraception questions, access, cost, and follow-up.
- Saxenda discussions usually focus on daily liraglutide use, weight-management criteria including adolescent considerations, heart-rate and mood-history review, missed-dose restart questions, pen supply, and whether the daily routine is realistic.
- Mounjaro and Victoza are diabetes-labeled products with related active ingredients but different labels; compounded tirzepatide or liraglutide adds a separate prescription, pharmacy-quality, and non-FDA-approved compounded-preparation discussion.